UroGen Pharma reports FY2022 JELMYTO revenue of $64.4M (+34% YoY); guides FY2023 revenue $76-86M

UroGen Pharma Ltd.

JELMYTO net revenue for FY2022: $64.4M, up 34% from $48.0M in FY2021; Q4 revenue: $18.1M.
Net loss for FY2022: $109.2M ($4.79/share) vs $110.8M ($4.96/share) in FY2021; cash ~$100M.
UGN-102 Phase 3 ENVISION fully enrolled (~220 patients); topline data for ENVISION and ATLAS expected mid-2023; NDA submission targeted for 2024.
FY2023 guidance: JELMYTO revenue $76-86M; operating expenses $135-145M; cash expected to fund operations into H1 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

UroGen Pharma Ltd. reported the full year ended December 31, 2022 results: revenue $64.4 million.

Period: the full year ended December 31, 2022
Revenue: $64.4 million
Result: reported results

Exact text from the filing

Net product revenues were $64.4 million for the full year 2022, compared to $48.0 million for the full year 2021.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

UroGen Pharma Ltd. reported the fourth quarter ended December 31, 2022 results: revenue $18.1 million.

Period: the fourth quarter ended December 31, 2022
Revenue: $18.1 million
Result: reported results

Exact text from the filing

UroGen reported JELMYTO net product revenues for the fourth quarter 2022 of $18.1 million, compared to $16.2 million for the same period in 2021.

View on SEC.gov

Browse all earnings releases →

UroGen Pharma Ltd. filing history →

Source: SEC EDGAR

accession 0001193125-23-076682

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.